Softwr

Research · head to head

Genedata vs LabVantage

Genedata logo

Genedata

Research

Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher

From
On request
Rated
-
Full reviewWebsite
LabVantage logo

LabVantage

Research

Enterprise LIMS with integrated ELN and biobanking capability

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; LabVantage enterprise implementation weight, with configuration and validation measured in many months
  • They diverge on capability: Genedata covers Screener, LabVantage covers Unified platform.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Genedata and LabVantage actually diverge.

Attributes where Genedata and LabVantage differ
AttributeGenedataLabVantage
PlatformsWeb, On-premise, Private cloudWeb, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Genedata

  • Screener
  • Biologics
  • Bioprocess
  • Expressionist
  • Selector
  • Profiler
  • GxP-capable deployments

Only in LabVantage

  • Unified platform
  • Biobanking
  • Industry accelerators
  • Regulatory compliance
  • Web architecture

Both cover

  • Instrument integration

What people use each for

The jobs each tool is most often brought in to do.

Genedata

  • A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot LabVantage
  • A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot LabVantage
  • A process development group standardising bioprocess run data across sites for modelling and scale-upnot LabVantage
  • A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot LabVantage

LabVantage

  • Laboratories wanting LIMS and ELN from one vendor rather than integrating twonot Genedata
  • Biobanks managing specimen provenance, consent and long-term storagenot Genedata
  • Pharmaceutical research organisations spanning discovery through QCnot Genedata
  • Multi-site laboratory networks standardising on a single platformnot Genedata

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Genedata

  • There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
  • Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
  • Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
  • Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
  • Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.

LabVantage

  • Enterprise implementation weight, with configuration and validation measured in many months
  • Pricing is quote-based with no public entry point
  • The unified platform argument only pays off for laboratories that genuinely need all four capabilities; those needing only LIMS may find focused competitors better
  • Smaller installed base than LabWare, which matters in conservative laboratory procurement
  • Industry accelerators shorten implementation but do not remove the need for laboratory-specific configuration

Pricing, plan by plan

Genedata

On request
  • Genedata platform licence$undefined/year
    • Each platform, such as Screener or Biologics, licensed separately
    • Annual enterprise subscription scoped on users, sites and data volume
    • Implementation and scientific configuration services quoted as a separate programme

LabVantage

On request
  • LabVantage$undefined/year
    • LIMS
    • ELN
    • LES

Which should you pick?

Choose Genedata if

  • You need screener.
  • You work on Web, On-premise, Private cloud.
  • You also want biologics.
Genedata review

Choose LabVantage if

  • You need unified platform.
  • You work on Web, Cloud, On-premise.
  • You also want biobanking.
LabVantage review

Questions people ask

Is Genedata or LabVantage better?
Neither clearly leads. Genedata starts at On request and LabVantage at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Genedata or LabVantage?
Genedata starts at On request and LabVantage at On request.
Does Genedata or LabVantage run on more platforms?
Genedata runs on Web, On-premise, Private cloud. LabVantage runs on Web, Cloud, On-premise.
What is Genedata best used for?
Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what LabVantage is typically brought in for.
What can Genedata do that LabVantage cannot?
Genedata covers Screener, Biologics, Bioprocess, Expressionist. LabVantage covers Unified platform, Biobanking, Industry accelerators, Regulatory compliance. Both handle Instrument integration.

Answered from the vendors’ own pages

Genedata: Who owns Genedata?

Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.

LabVantage: What does the unified platform actually mean?

LIMS, electronic laboratory notebook, laboratory execution and scientific data management as one product. Laboratories that would otherwise integrate and validate four vendors avoid that work.

Genedata: Is there a small-team or starter option?

No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.

LabVantage: Is biobanking really different?

Yes. Specimen provenance, consent tracking and decades-long storage are distinct from test result management, and the number of platforms handling them properly is small.

Genedata: Do I buy one product or the whole suite?

Each platform is licensed separately. Most customers license two or three and integrate between them.

LabVantage: What does it cost?

Not published. Enterprise annual licensing plus implementation, quoted on scope.

Genedata: Can it be used in a GxP environment?

Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.

LabVantage: Do the industry accelerators shorten implementation?

They help by supplying pre-configured workflows for a vertical. They do not remove laboratory-specific configuration or, in regulated settings, validation.

LabVantage: How does it compare to LabWare?

LabWare has the larger installed base and deeper pharmaceutical QC dominance. LabVantage argues on the unified LIMS and ELN platform and on biobanking. Both are enterprise projects.

Share

Related pages

More on Genedata

More on LabVantage

Keep looking

Other head to heads